The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 22, 2012
Filed:
Jul. 20, 2011
Yi Chen, San Mateo, CA (US);
Timothy D. Cushing, Pacifica, CA (US);
Xiaolin Hao, Foster City, CA (US);
Xiao He, Foster City, CA (US);
Andreas Reichelt, Moorpark, CA (US);
Robert M. Rzasa, Ventura, CA (US);
Jennifer Seganish, Scotch Plains, NJ (US);
Youngsook Shin, Emeryville, CA (US);
Dawei Zhang, Thousand Oaks, CA (US);
Yi Chen, San Mateo, CA (US);
Timothy D. Cushing, Pacifica, CA (US);
Xiaolin Hao, Foster City, CA (US);
Xiao He, Foster City, CA (US);
Andreas Reichelt, Moorpark, CA (US);
Robert M. Rzasa, Ventura, CA (US);
Jennifer Seganish, Scotch Plains, NJ (US);
Youngsook Shin, Emeryville, CA (US);
Dawei Zhang, Thousand Oaks, CA (US);
Amgen Inc., Thousand Oaks, CA (US);
Abstract
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.